Header Logo

Connection

JOHN KIRKWOOD to CTLA-4 Antigen

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about CTLA-4 Antigen.
JOHN KIRKWOOD
Connection Strength
1.812
CTLA-4 Antigen
  1. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-a or TLR-9 agonist and GM-CSF with peptide vaccination. J Immunother. 2012 Nov-Dec; 35(9):702-10.
    View in: PubMed
    Score: 0.409
  2. Assessing clonal changes in T?cells over time following immunotherapy is a breeze with Cyclone. Cancer Cell. 2024 Sep 09; 42(9):1491-1493.
    View in: PubMed
    Score: 0.233
  3. CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
    View in: PubMed
    Score: 0.181
  4. PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: Understanding the Upside of the Downside of Checkpoint Blockade. JAMA Oncol. 2019 07 01; 5(7):942-943.
    View in: PubMed
    Score: 0.162
  5. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight. 2017 09 21; 2(18).
    View in: PubMed
    Score: 0.144
  6. Adjuvant therapy for melanoma. Cancer J. 2012 Mar-Apr; 18(2):192-202.
    View in: PubMed
    Score: 0.098
  7. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Oncology (Williston Park). 2010 Dec; 24(14):1302, 1304.
    View in: PubMed
    Score: 0.090
  8. Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. J Transl Med. 2010 Nov 03; 8:108.
    View in: PubMed
    Score: 0.089
  9. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers. Expert Opin Biol Ther. 2008 Oct; 8(10):1583-93.
    View in: PubMed
    Score: 0.077
  10. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
    View in: PubMed
    Score: 0.076
  11. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther. 2007 Oct; 9(5):505-14.
    View in: PubMed
    Score: 0.072
  12. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
    View in: PubMed
    Score: 0.050
  13. Impact of checkpoint blockade on cancer vaccine-activated CD8+ T cell responses. J Exp Med. 2020 07 06; 217(7).
    View in: PubMed
    Score: 0.044
  14. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019 09 04; 7(1):239.
    View in: PubMed
    Score: 0.041
  15. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS One. 2012; 7(7):e40805.
    View in: PubMed
    Score: 0.025
  16. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.